Skip to main content

Maria Buti Ferret

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Maria Buti Ferret

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

Immune profiling to guide host-directed interventions to cure HBV infections

IP: Maria Buti Ferret
Collaborators: Tamara Del Rio Higueras, Mª Eulàlia Molinas Guilera, Amaia Latasa Arrazubi, Judit Vico Romero, Alejandro López Targa, Maria del Mar Riveiro Barciela
Funding agency: EUROPEAN COMMISSION
Funding: 211443.8
Reference: IP-CURE-B_H2020SC1BHC2019
Duration: 01/01/2020 - 31/12/2024

Estudio prospectivo para identificar nuevos marcadores plasmáticos de replicación viral en pacientes con hepatitis crónica por virus de la hepatitis B (VHB) y/o Delta (VHD)

IP: Maria Buti Ferret
Collaborators: Maria del Mar Riveiro Barciela, Adriana Palom Agusti, Maria Francesca Cortese
Funding agency: Instituto de Salud Carlos III
Funding: 224757.5
Reference: PI17/02233
Duration: 01/01/2018 - 31/12/2021

Carotid atherosclerosis and chronic hepatitis B: role of persistent viral suppression and immunemediated response. A prospective study.

IP: Maria Buti Ferret
Collaborators: Maria del Mar Riveiro Barciela
Funding agency: GILEAD SCIENCES SLU
Funding: 49005
Reference: GLD16_00057
Duration: 14/12/2016 - 13/12/2018

Análisis de la interacción de los virus de la hepatitis B y D con el receptor del hepatocito y estudio prospectivo de la complejidad de sus quasiespecies virales

IP: Maria Buti Ferret
Collaborators: Lluís Viladomiu Catà, Maria del Mar Riveiro Barciela, Carolina Gonzalez Fernandez, David Tabernero Caellas
Funding agency: Instituto de Salud Carlos III
Funding: 147015
Reference: PI14/01416
Duration: 01/01/2015 - 31/12/2017

Related news

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

Related professionals

Fernando Trejo Velasco

Fernando Trejo Velasco

Predoctoral researcher
Ophtalmology
Read more
Alicia Inés García Señán

Alicia Inés García Señán

Predoctoral researcher
Microbiology
Read more
Mónica Linares Alberich

Mónica Linares Alberich

Research technician
Transfusional Medicine
Read more
Carmen Montanero Gallardo

Carmen Montanero Gallardo

Transfusional Medicine
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.